MedTrace Logo

Comparison of Effects of Buffered and Enteric-coated Forms of Aspirin on Platelet Aggregation in Patients With Diabetes Mellitus and Chronic Coronary Syndrome

NCT06716255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-12-04

No results posted yet for this study

Summary

Patients with diabetes mellitus are characterized by "hyperreactive" platelets and a reduced response to ASA compared to individuals without diabetes. ASA that is absorbed in the intestine is slower to enter the bloodstream and become therapeutic concentrations compared to ASA that is absorbed in the stomach. It seems rational to test the hypothesis that the use of buffered ASA may be more effective in patients with diabetes and chronic coronary syndrome (CCS).

Conditions

  • Diabetes Mellitus Type 2
  • Coronary Artery Diseases
  • Aspirin Resistance

Sponsors & Collaborators

  • Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache

    collaborator OTHER

  • Nizhpharm

    lead OTHER

Principal Investigators

  • Imad Akhmad Merai, Head of CCU · University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-05-17
Completion
2024-09-24

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716255 on ClinicalTrials.gov